Results 11 to 20 of about 20,100 (304)

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan

Therapeutic Advances in Neurological Disorders, 2023
Background: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS ...
Ichiro Nakashima, Jin Nakahara, Hiroaki Yokote, Yasuhiro Manabe, Kazumi Okamura, Kou Hasegawa, Kazuo Fujihara   +6 more
doaj   +2 more sources

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +2 more sources

Treating C3 glomerulopathy with eculizumab [PDF]

BMC Nephrology, 2018
Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte, Frederic Arnold, Julia Kappes, Maximilian Seidl, Karsten Häffner, Carsten Bergmann, Gerd Walz, Elke Neumann-Haefelin   +7 more
doaj   +5 more sources

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

JCI Insight, 2023
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target ...
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck   +14 more
doaj   +2 more sources

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BMC Nephrology, 2023
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner   +6 more
doaj   +2 more sources

Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network

Hematology Reports, 2023
Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman, Seth Kuranz, Michael M. Yeh, Kaylen Brzozowski, Herman Chen   +4 more
doaj   +2 more sources

Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis [PDF]

Nephron Clinical Practice, 2014
A major shift in our understanding of the membranoproliferative glomerulonephritis (MPGN) lesion is the focus on which components of the complement pathway are involved in mediating renal injury. Hence, MPGN is no longer classified solely by ultrastructural findings on biopsy but instead divided into immune complex-mediated lesions versus complement ...
Andrew S. Bomback
openalex   +3 more sources

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.

New England Journal of Medicine, 2021
BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis ...
P. Hillmen, J. Szer, I. Weitz, A. Röth, B. Höchsmann, J. Panse, K. Usuki, M. Griffin, J. Kiladjian, Carlos M. de Castro, H. Nishimori, L. Tan, M. Hamdani, Pascal Deschatelets, C. Francois, F. Grossi, T. Ajayi, A. Risitano, Régis Peffault de la Tour   +18 more
semanticscholar   +1 more source

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin–Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial

Journal of the American Society of Nephrology, 2023
Visual Abstract Significance Statement Shiga toxin–related hemolytic uremic syndrome (STEC-HUS) is a serious condition, characterized by multiorgan thrombotic microangiopathy, mainly affecting children.
A. Garnier, K. Brochard, T. Kwon, A. Sellier-Leclerc, A. Lahoche, Emma Allain Launay, F. Nobili, M. Caillez, S. Taque, J. Harambat, Guylhene Michel-Bourdat, V. Guigonis, M. Fila, S. Cloarec, D. Djamal-Dine, Loïc de Parscaux, Lise Allard, R. Salomon, T. Ulinski, V. Frémeaux-Bacchi, Christophe Morin, P. Olivier‐Abbal, H. Colineaux, F. Auriol, C. Arnaud, I. Kieffer, Clara Brusq   +26 more
semanticscholar   +1 more source

Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series

Brain Sciences, 2021
(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on
Marco Allinovi, Angelo Bellinvia, Francesco Pesce, Sabrina Milan Manani, Lorenzo Razzolini, Brigida Brezzi, Paolo Protopapa, Vittorio Mantero, Leonardo Caroti, Calogero Lino Cirami, Maria Pia Amato, Lucia Del Vecchio   +11 more
doaj   +1 more source